We analyzed donor-type chimerism in CD3 þ , CD14.15 þ and CD56 þ cells from 36 patients who had undergone conventional-intensity allogeneic stem cell transplantation (CST) and 34 patients who had undergone nonmyeloablative allogeneic stem cell transplantation (NST) for hematological malignancies. On day 28 after transplantation, all fractions in NST patients and CD3 þ cells in CST patients who received a non-total body irradiation (TBI) regimen showed more frequent mixed chimerism (o90% donor cells) than those in patients who had received TBI. NST patients with acute graft-versushost disease (grade II-IV) frequently showed more than 50% donor-type chimerism in CD3 þ cells on day 14 (P ¼ 0.029). NST patients with o50% donor-type chimerism on day 14 and with o90% donor-type chimerism on day 28 in CD56 þ cells had significantly poor 1-year overall survival (0 vs 91%, Po0.001 and 20 vs 74%, P ¼ 0.002, respectively). Both NST and CST patients with o90% donor-type chimerism in CD14.15 þ cells on day 28 had significantly poor 1-year overall survival (14 vs 70%, P ¼ 0.005 and 0 vs 66%, P ¼ 0.002, respectively). Our data show that the extent of donor-type chimerism in lineage-specific cells appears to have an impact on outcome after allogeneic stem cell transplantation.
Introduction
Allogeneic nonmyeloablative stem cell transplantation (NST) is useful in patients ineligible for conventional transplants. [1] [2] [3] [4] [5] [6] Since some patients develop mixed chimerism (MC) and rejection, it is important to analyze donor cell engraftment. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] It has been reported that CD3 þ cell chimerism is most predictive of successful engraftment. Antin et al. 8 reported that patients with more than 90% donor T cells developed acute graft-versus-host disease (aGVHD) more frequently than did patients with less than 90% donor T cells. Keil et al. 9 reported that patients with less than 90% donor T cells had rejection and relapse more frequently than did patients with more than 90% donor T cells. On the other hand, NK cells are also important for achievement of engraftment and for regulation of GVHD and graft-versus-leukemia (GVL). [22] [23] [24] In this study, we separated peripheral blood mononuclear cells (PBMCs) into lineage-specific cell populations, such as CD3 þ T cells, CD14.15 þ myeloid cells and CD56 þ NK cells, and analyzed the relationships between donor-type chimerism by quantitative microsatellite amplification and outcome.
Patients and methods

Patients
We collected PBMCs from 70 patients who had undergone allogeneic stem cell transplantation for hematological malignancies between November 2000 and September 2005. Patient characteristics are shown in Table 1 . Thirtysix patients received allogeneic conventional myeloablative stem cell transplantation (CST) and 34 patients received NST (two patients received a second NST because of rejection after the first NST). These patients received transplantation of serologically HLA-matched sibling marrow or blood stem cells, serologically HLA-matched unrelated marrow and up to two-locus-mismatched cord blood. Most of the patients received conditioning regimens consisting of VP-16 (VP, 15 mg/kg/day for 2 days) þ cyclophosphamide (CY, 60 mg/kg/day for 2 days) þ total body irradiation (TBI) (12 Gy in six fractions) for myeloablative conditioning. 25 NST patients received fludarabine-based regimens without TBI (n ¼ 19) or fludarabine-based regimens with TBI (n ¼ 15). Administration of cyclosporine A (CsA, 3 mg/kg) or FK506 (FK, 0.03 mg/kg) with or without short-course methotrexate (sMTX; 15 mg/m 2 on day 1, 10 mg/m 2 on day 3 and 10 mg/m 2 on day 6) comprised GVHD prophylaxis. The study protocol was approved by the review board of Hokkaido University Graduate School of Medicine.
Methods
We obtained peripheral blood from recipients before allogeneic stem cell transplantation, and also from the donors or donor DNA from the grafts. After transplantation, PBMCs were collected from recipients 2 weeks (when WBCs were available for the analysis), 4 weeks, 2 months and 3 months after transplantation. Whole mononuclear cells (whole) were fractionated into CD3 þ , CD14.CD15 þ and CD56 þ cells using a magnetic cell sorter (MACS, Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) from 3 Â 10 6 cells. Purities of these cells were more than 80% (data not shown). DNA was extracted from each cell fraction by using a QIAamp DNA Blood Mini Kit (QIAGEN, Germany).
Four types of microsatellite primer (D3S1359, D6S89, ACTBP2, HGH) were used in this study, and each microsatellite primer was labeled with three types of fluorescence (6FAM, HEX and NED). All samples were carried out in a 100-ml reaction mixture containing 0.2 mM dNTP, 2 mM MgCl 2 , 2 mM Tris-HCl, 10 mM KCl, 0.01 mM EDTA, 50 pmol of each primer and 1.5 U of TaKaRa Ex Taq polymerase. PCR was performed at 951C for 1 min, 551C for 1 min and 721C for 1 min for amplification for 30 cycles. The PCR reaction using 50-200 ng template DNA was carried out using a GeneAmp PCR System 9700 (Applied Biosystems, Foster City, CA, USA). PCR product (1 ml) was mixed with a size standard sample (labeled with ROX) and paraformamide. After heating at 951C for 2 min, the sample was placed on ice. The sample was analyzed using a capillary electrophoresis system (ABI PRISM310 Genetic Analyzer) as reported previously. 11, 12 The sensitivity was 3% and donor complete chimerism (CC) was defined as more than 90% donor cells. Student's t test was used to analyze differences between chimerism and several clinical factors such as TBI, aGVHD, rejection and relapse. Overall survival was analyzed by the method of Kaplan and Meier.
Results
Hematologic recovery
The median follow-up period for CST patients was 15 months (range, 1-52 months). The median periods required for recovery of absolute neutrophil count to more than 500/ml and recovery of platelet count to more than 50 000/ml were 16 days (range, 11-40 days) and 25 days (17-60 days), respectively. The median follow-up period for NST patients was 11 months (range, 1-61 months). The median periods required for recovery of absolute neutrophil count to more than 500/ ml and recovery of platelet count to more than 50 000/ml were 16 days (range, 8-46 days) and 29 days (14-157 days), respectively.
Analysis of chimerism in patients who underwent conventional-intensity allogeneic stem cell transplantation On day 28, the amount of donor cells in CD3 þ , CD14.15 þ and CD56 þ cells was 92.6, 97.6 and 95.2%, respectively. At 3 months, the average percentages of donor cells in all cell fractions were more than 97% (data not shown).
At 1 month after transplantation, patients who did not receive TBI in the preparative regimen frequently showed MC (donor cells o90%) in CD3 þ cells (4/7 patients vs 2/ 26 patients, P ¼ 0.02) ( Table 2) , and patients with aGVHD frequently showed CC in CD3 þ cells (14/26 patients vs 0/7 patients, P ¼ 0.009). Patients with MC in CD14.15 þ cells frequently relapsed (3/3 patients vs 9/30 patients, P ¼ 0.015) (Table 3a) . Furthermore, patients with donor-type chimerism of less than 90% in CD14.15 þ cells on day 28 had significantly poorer 1-year overall survival (0% n ¼ 3 vs 66% n ¼ 30, P ¼ 0.002, Table 4a, Figure 1a ). Mixed chimerism (donor cells o90%) in all fractions was frequently observed in patients who received a non-TBI regimen (Table 2) . We divided the ratios of donor chimerism into 0-50 and 51-100% on day 14, and into 0-75 and 76-100% on day 28 (1 month) (Table 3b) . Patients who had more than 50% of donor chimerism in CD3 þ cells on day 14 frequently developed aGVHD of more than grade II (7/14 patients vs 1/11 patients, P ¼ 0.029). Patients who had donor chimerism of less than 50% in CD56 þ cells on day 14 had significantly more frequent rejection (2/ 3 patients vs 0/10 patients, P ¼ 0.002). A similar tendency was found in CD3 þ cells (3/7 patients vs 0/11 patients, P ¼ 0.016). Patients who had donor chimerism of less than 50% in CD56 þ cells on day 14 relapsed more frequently (3/3 patients vs 2/12 patients, P ¼ 0.029). Also, patients with less than 75% donor cells in all fractions on day 28 frequently developed rejection and relapse. Furthermore, patients with donor chimerism of more than 90% in CD14.15 þ cells on day 28 and donor chimerism of more than 50% on day 14 and more than 90% on day 28 in CD56 þ cells showed better 1-year overall survival (70 vs 14%, P ¼ 0.005; 91 vs 0%, Po0.001; 74 vs 20%, P ¼ 0.002, respectively) (Table 4a and Figure 1b-d) . Nonmyeloablative allogeneic stem cell transplantation patients with more than 75% of donor CD14.15 þ cells on day 28 had good overall survival (P ¼ 0.031, data not shown).
Analysis of chimerism in patients who
We also grouped the patients according to whether the patients had detectable autologous cells or did not have detectable autologous cells (less than 3% of autologous cells). In this respect, NST patients with donor chimerism of more than 97% in CD14.15 þ cells and CD56 þ cells on day 28 showed better 1-year overall survival (70% n ¼ 24 vs 30% n ¼ 10, P ¼ 0.037; 76% n ¼ 22 vs 25% n ¼ 12, P ¼ 0.003, respectively) (Table 4b) .
In order to consider the dynamics of the chimerism evolution, we grouped the patients into those who had CC or decreasing MC (CC on day 14 and day 28 or MC on day 14 and more than 90% of donor cells (CC) on day 28) and those who had MC or increasing MC (MC on day 14 and day 28 or CC on day 14 and MC on day 28). Patients with CC or decreasing MC in CD14.15 þ and CD56 þ cells showed better 1-year overall survival than did patients with MC or increasing MC (77% n ¼ 13 vs 0% n ¼ 4, P ¼ 0.006; 91% n ¼ 11 vs 0% n ¼ 5, P ¼ 0.001, respectively).
Discussion
Chimerism is best analyzed by amplification of microsatellites. 11, 13 Chimerism analysis allows detection of impending graft rejection or recurrence. Some patients could show complete chimerism in one cell compartment, whereas other cell compartments could be totally or in part recipient-derived, so-called 'split chimersim'. 20 Therefore, it is important to analyze chimerism not only in whole PBMCs but also in lineage-specific cell populations. Although the importance of chimerism analysis in T cells has been reported, 8, 9, 17, 19 we speculated that other cells such as CD14.15 þ myeloid cells and NK cells play an important role in the regulation of rejection, GVHD and relapse. 
Analysis of donor-type chimerism after allogeneic SCT Y Miura et al
Most patients who had undergone CST showed CC (donor cells 490%) at 1 month after transplantation. However, a non-TBI regimen often induced MC in CD3 þ cells at 1 month after transplantation. Conventionalintensity allogeneic stem cell transplantation patients with CC in CD3 þ cells at 1 month after transplantation had aGVHD more often than did those with MC.
Also, a TBI regimen induced faster engraftment and CC in all fractions more rapidly in patients who underwent NST in our study. In patients who underwent NST, the order of recovery in each fraction was CD14.15 þ , CD56 þ , and then CD3 þ cells. While Childs et al. 7 reported that donor T cells recovered faster than did other cells, other studies have shown that donor myeloid and NK cells recovered faster than did donor T cells. [16] [17] [18] [19] The findings in the latter studies are consistent with the present results. The conditioning regimen may influence the engraftment kinetics of lymphocytes and also other cells.
Nonmyeloablative allogeneic stem cell transplantation patients with donor chimerism in CD3 þ cells of more than 50% on day 14 developed significantly more frequent aGVHD of more than grade II than did patients with that less than 50%. The proportion of donor CD3 þ cells may be useful for early prediction of aGVHD. Several patients showed MC in CD3 þ cells when they developed aGVHD and afterwards achieved CC. Similar results were reported by Petersen et al., 19 who found that aGVHD appeared in patients with MC in T cells and then finally they achieved CC after NST with a Flu þ TBI regimen. New approaches aimed at reducing the incidence of grade II-IV aGVHD might improve survival after NST. 26 Information on donor-type chimerism in CD3 þ cells early after NST may be valuable for modulation of immunosuppressive drugs. Lassaletta et al. 27 reported that full donor chimerism in whole blood by day 30 after allogeneic PBSCT was associated with a low risk of relapse in pediatric patients with hematological malignancies. Nonmyeloablative allogeneic stem cell transplantation patients with donor chimerism of less than 50% in CD56 þ cells on day 14 had significantly more frequent rejection and poor overall survival. Although a previous study suggested that MC in T cells causes rejection, 10 our study suggested the importance of donor chimerism in NK cells early after NST on day 14 for engraftment. Our lineage-specific chimerism analysis suggested that MC in CD56 þ cells might be a predictor of prognosis after SCT. Barron et al. 28 reported that low donor T-cell and NK-cell chimerism levels on day 14 were associated with increased probability of graft rejection and that earlier establishment of donor NK cell chimerism was associated with improved progression-free survival in patients who had undergone NST. Although KIR-ligand incompatibility about NK cell alloreactivity was not estimated, our findings support their results.
Also, MC in CD14.15 þ cells at 1 month after NST correlated well with relapse of myeloid leukemia. In contrast, both CST patients and NST patients with more than 90% of donor CD14.15 þ cells at 1 month after transplantation had good overall survival. Michallet et al. 29 reported that chimerism status had a major impact on overall survival after SCT following either a conventional or a reduced-intensity regimen and that MC kinetics was Overall survival was analyzed by the method of Kaplan and Meier. We divided % donor chimerism into 0-50 and 51-100% on day 14 after allo-NST and into 0-89 and 90% on day 28 after allo-CST and allo-NST. Abbreviations: CST ¼ conventional-intensity allogeneic stem cell transplantation; NS ¼ not significant; NST ¼ nonmyeloablative allogeneic stem cell transplantation. Overall survival was analyzed by the method of Kaplan and Meier. We divided % donor chimerism into 0-97% and over 98% on day 28 after allo-CST and allo-NST. Abbreviations: CST ¼ conventional-intensity allogeneic stem cell transplantation; NS ¼ not significant; NST ¼ nonmyeloablative allogeneic stem cell transplantation.
the most powerful variable for predicting relapse. Zeiser et al. 21 reported that conventional chimerism analysis (in vitro sensitivity less than 3%) and lineage-specific chimerism analysis (in vitro sensitivity less than 0.1%) in CD34 þ and CD3 þ cells were comparatively sensitive and specific for relapse at mean intervals of 24 days (range: 11-116) in patients with myeloid malignancies. Bader et al. 20 recommended MC analysis at weekly intervals until day 200 post transplantation for malignant disease using whole PBMCs and using lineage-specific cells when graft failure is suspected. Also, in patients with increasing MC, consideration should be given to withdrawing immunosuppressive drugs or performing donor lymphocyte infusion (DLI). 20, 21 Therefore, chimerism analysis after SCT is very important for the surveillance of engraftment and recurrence of the underlying disease.
In conclusion, analysis of donor-type chimerism in lineage-specific cells early after transplantation might be useful for monitoring clinical outcome after both CST and NST.
